Corcept Therapeutics CORT Change in AR
Change in AR at other companies
Other financials
Where this comes from
Reported directly by Corcept Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:IncreaseDecreaseInAccountsReceivable.
The official record: Corcept Therapeutics’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Corcept Therapeutics's change in ar.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Corcept Therapeutics's change in AR?
- Corcept Therapeutics (CORT) reported change in AR of -$20.71M in Q1 2026.
- How has Corcept Therapeutics's change in AR changed year-over-year?
- Corcept Therapeutics's change in AR decreased by 364.1% year-over-year, from $7.84M to -$20.71M.
- What does change in AR mean?
- The change in money owed to the company by its customers.
- How do you interpret change in AR?
- An increase in receivables consumes cash, potentially signaling slower collection cycles or aggressive revenue recognition.
- How does change in AR compare across companies?
- Monitored closely by investors to assess the quality of earnings and cash conversion efficiency.